Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response
dc.contributor.buuauthor | Atasayar, Gülfer | |
dc.contributor.buuauthor | Eryılmaz, Işıl Ezgi | |
dc.contributor.buuauthor | Karlı, Necdet | |
dc.contributor.buuauthor | Egeli, Ünal | |
dc.contributor.buuauthor | Zarifoğlu, Mehmet | |
dc.contributor.buuauthor | Çeçener, Gülşah | |
dc.contributor.buuauthor | Taşkapılıoğlu, Özlem | |
dc.contributor.buuauthor | Tunca, Berrin | |
dc.contributor.buuauthor | Yıldırım, Öznur | |
dc.contributor.buuauthor | Ak, Seçil | |
dc.contributor.buuauthor | Tezcan, Gülçin | |
dc.contributor.buuauthor | Can, Fatma Ezgi | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-1619-6680 | tr_TR |
dc.contributor.orcid | 0000-0002-3820-424X | tr_TR |
dc.contributor.orcid | 0000-0002-3316-316X | tr_TR |
dc.contributor.orcid | 0000-0001-7904-883X | tr_TR |
dc.contributor.orcid | 0000-0002-1953-7735 | tr_TR |
dc.contributor.orcid | 0000-0002-5956-8755 | tr_TR |
dc.contributor.researcherid | ABI-6078-2020 | tr_TR |
dc.contributor.researcherid | AAP-9988-2020 | tr_TR |
dc.contributor.researcherid | AAH-1656-2021 | tr_TR |
dc.contributor.researcherid | GWV-3548-2022 | tr_TR |
dc.contributor.researcherid | AAH-3843-2020 | tr_TR |
dc.contributor.researcherid | F-8554-2017 | tr_TR |
dc.contributor.researcherid | AAH-1420-2021 | tr_TR |
dc.contributor.scopusid | 57189387392 | tr_TR |
dc.contributor.scopusid | 57189380840 | tr_TR |
dc.contributor.scopusid | 6506587942 | tr_TR |
dc.contributor.scopusid | 55665145000 | tr_TR |
dc.contributor.scopusid | 6603411305 | tr_TR |
dc.contributor.scopusid | 6508156530 | tr_TR |
dc.contributor.scopusid | 23037226400 | tr_TR |
dc.contributor.scopusid | 6602965754 | tr_TR |
dc.contributor.scopusid | 57189390647 | tr_TR |
dc.contributor.scopusid | 55253485700 | tr_TR |
dc.contributor.scopusid | 25650627600 | tr_TR |
dc.contributor.scopusid | 56689608500 | tr_TR |
dc.date.accessioned | 2022-12-12T12:02:03Z | |
dc.date.available | 2022-12-12T12:02:03Z | |
dc.date.issued | 2016-05-11 | |
dc.description.abstract | Prophylactic therapy response varies in migraine patients. The present study investigated the relationship between the resistance to the drugs commonly used in prophylactic therapy and the possible polymorphic variants of proteins involved in the metabolism of these drugs. Migraine patients with the MDR1 3435TT genotype exhibited a better treatment response to topiramate than migraine patients with the CC and CT genotypes (p = 0.020). The MDR1 C3435T polymorphism was also found to be a higher risk factor for topiramate treatment failure in a comparison of the number of days with migraine (beta(2) = 1.152, p = 0.015). However, there was no significant relationship between the treatment response to topiramate and either the CYP2D6 or CYP2C19 polymorphism, and there were no significant correlations between the treatment responses to amitriptyline, propranolol, and valproic acid and the MDR1, CYP2D6 and CYP2C19 gene polymorphisms. This is the first study to investigate the effect of the polymorphic variants on prophylactic therapy response in migraine patients. | en_US |
dc.identifier.citation | Atasayar, G. vd. (2016). "Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response". Journal of the Neurological Sciences, 366, 149-154. | en_US |
dc.identifier.endpage | 154 | tr_TR |
dc.identifier.issn | 0022-510X | |
dc.identifier.issn | 1878-5883 | |
dc.identifier.pubmed | 27288795 | tr_TR |
dc.identifier.scopus | 2-s2.0-84969944998 | tr_TR |
dc.identifier.startpage | 149 | tr_TR |
dc.identifier.uri | https://doi.org/10.1016/j.jns.2016.05.019 | |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0022510X16302787 | |
dc.identifier.uri | http://hdl.handle.net/11452/29826 | |
dc.identifier.volume | 366 | tr_TR |
dc.identifier.wos | 000379105400030 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.journal | Journal of the Neurological Sciences | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Neurosciences & neurology | en_US |
dc.subject | Migraine | en_US |
dc.subject | Prophylactic therapy response | en_US |
dc.subject | MDR1 | en_US |
dc.subject | Polymorphism | en_US |
dc.subject | Multidrug-resistance | en_US |
dc.subject | C3435t polymorphism | en_US |
dc.subject | Cytochrome-P450 | en_US |
dc.subject | Frequency | en_US |
dc.subject | Alleles | en_US |
dc.subject | Pharmacogenetics | en_US |
dc.subject | Phenotype | en_US |
dc.subject | Genotype | en_US |
dc.subject | 2C19 | en_US |
dc.subject | 2D6 | en_US |
dc.subject.emtree | Amitriptyline | en_US |
dc.subject.emtree | Cytochrome P450 2C19 | en_US |
dc.subject.emtree | Cytochrome P450 2D6 | en_US |
dc.subject.emtree | Genomic DNA | en_US |
dc.subject.emtree | Multidrug resistance protein 1 | en_US |
dc.subject.emtree | Propranolol | en_US |
dc.subject.emtree | Topiramate | en_US |
dc.subject.emtree | Valproic acid | en_US |
dc.subject.emtree | ABCB1 protein, human | en_US |
dc.subject.emtree | Central nervous system agents | en_US |
dc.subject.emtree | CYP2C19 protein, human | en_US |
dc.subject.emtree | Cytochrome P450 2C19 | en_US |
dc.subject.emtree | Cytochrome P450 2D6 | en_US |
dc.subject.emtree | Fructose | en_US |
dc.subject.emtree | Multidrug resistance protein | en_US |
dc.subject.emtree | Topiramate | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | DNA polymorphism | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Gene frequency | en_US |
dc.subject.emtree | Genetic association | en_US |
dc.subject.emtree | Genotype | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Migraine | en_US |
dc.subject.emtree | Migraine with aura | en_US |
dc.subject.emtree | Migraine without aura | en_US |
dc.subject.emtree | Monotherapy | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Prophylaxis | en_US |
dc.subject.emtree | Treatment response | en_US |
dc.subject.emtree | Analogs and derivatives | en_US |
dc.subject.emtree | Drug resistance | en_US |
dc.subject.emtree | Genetic association study | en_US |
dc.subject.emtree | Genetic polymorphism | en_US |
dc.subject.emtree | Genetics | en_US |
dc.subject.emtree | Migraine disorders | en_US |
dc.subject.emtree | Risk factor | en_US |
dc.subject.emtree | Treatment outcome | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Amitriptyline | en_US |
dc.subject.mesh | Central nervous system agents | en_US |
dc.subject.mesh | Cytochrome P-450 CYP2C19 | en_US |
dc.subject.mesh | Cytochrome P-450 CYP2D6 | en_US |
dc.subject.mesh | Drug resistance | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Fructose | en_US |
dc.subject.mesh | Gene frequency | en_US |
dc.subject.mesh | Genetic association studies | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Migraine disorders | en_US |
dc.subject.mesh | P-glycoproteins | en_US |
dc.subject.mesh | Polymorphism, genetic | en_US |
dc.subject.mesh | Propranolol | en_US |
dc.subject.mesh | Risk factors | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.subject.mesh | Valproic acid | en_US |
dc.subject.scopus | Drug Resistant Epilepsy; Epilepsy; Carbamazepine | en_US |
dc.subject.wos | Clinical neurology | en_US |
dc.subject.wos | Neurosciences | en_US |
dc.title | Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response | en_US |
dc.type | Article | |
dc.wos.quartile | Q3 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: